Dr. Keith Walley is the Director of UBC’s Center for Heart Lung Innovation (HLI) located at St Paul’s Hospital. Dr. Walley received his MD from the University of Manitoba in 1981, trained in Internal Medicine at McGill University, and subsequently trained in Critical Care Medicine at the University of Chicago. He has been a practicing Intensivist at St. Paul’s Hospital ICU and investigator at the HLI laboratories for many years.
The focus of Dr. Walley’s research is to investigate 1) the mechanism of decreased left ventricular contractility and other organ failure during sepsis and 2) the impact of genotype on patient outcomes in sepsis and systemic inflammatory states. He collaborates on clinical trials involving critically ill patients to translate basic discoveries into clinical practice in the ICU. He has co-founded two research based companies namely, Sirius Genomics (2001) and Cyon Therapeutics (2014) along with his HLI colleagues.